Treatment of Upper Limb Chronic Neuropathic Pain by Electrical Stimulation of the Brachial Plexus Nerve Roots

Neuralgia Clinical Trial

— SIMPLEX  

Official title:

Treatment of Upper Limb Chronic Neuropathic Pain by Electrical Stimulation of the Brachial Plexus Nerve Roots

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05817786
• Other study ID #: 20-APN-01
• Secondary ID: 2021-A02538-33
• Status: Recruiting
• Phase: N/A
• Start date: January 31, 2024
• Est. completion date: October 1, 2025

Study information

• Verified date: January 2024
• Source: Centre Hospitalier Universitaire de Nice
• Contact: DENYS FONTAINE
• Phone: 0492034702
• Email: fontaine.D[@]chu-nice.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Moderate to severe neuropathic pain has a prevalence of 5% in the French population, involving the upper limb (UL) in 47%. Invasive neuromodulation, mainly spinal cord stimulation (SCS) is recommended as a third line treatment in refractory chronic neuropathic pain when optimized medical treatments are not sufficient to control pain.

The implantation technique for BP roots PNS is based on the ultrasound-guided percutaneous inter-scalenic approach, routinely used for BP anesthetic blocks. As for SCS, BP PNS relies on chronic electrical stimulation of the nerve roots via chronically implanted devices (one lead connected to a subcutaneous generator).

However efficacy of BP PNS has never been evaluated in controlled conditions. Our objectives are to assess, in controlled conditions, the effects of BP PNS in term of pain relief, quality of life improvement and safety.

Description:

Moderate to severe neuropathic pain has a prevalence of 5% in the French population, involving the upper limb (UL) in 47% . Invasive neuromodulation, mainly spinal cord stimulation (SCS) is recommended as a third line treatment in refractory chronic neuropathic pain when optimized medical treatments are not sufficient to control pain. However, SCS implanted at the cervical level, required to control UL pain, has shown its efficacy but has specific technical issues that limit its use: lead dislocation or breakage (0-43%), lead migration (0-12,5%), unwanted paresthesias in the trunk or the lower limb(s) (17%), paresthesias changes during head movements (48%). To avoid these limitations, peripheral nerve stimulation (PNS) targeting the UL nerve trunks or nerve roots of the brachial plexus (BP) has been proposed in short pioneering series reporting encouraging results .

The implantation technique for BP roots PNS is based on the ultrasound-guided percutaneous inter-scalenic approach, routinely used for BP anesthetic blocks. As for SCS, BP PNS relies on chronic electrical stimulation of the nerve roots via chronically implanted devices (one lead connected to a subcutaneous generator).

In a recent prospective series of 26 patients suffering from UL refractory pain, we reported that 20 patients still using the stimulation at last follow-up (28 months) experienced a mean pain relief of 67%. Seventeen patients were improved ≥50%, including 12 improved ≥70%. Complications were rare: stimulation intolerance due to shock-like sensations, superficial infection, lead fractures and lead migration . However efficacy of BP PNS has never been evaluated in controlled conditions. Our objectives are to assess, in controlled conditions, the effects of BP PNS in term of pain relief, quality of life improvement and safety.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 48
• Est. completion date: October 1, 2025
• Est. primary completion date: September 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Months to 80 Years

Eligibility

Inclusion Criteria:

• Eligibility will be determined by trained clinicians with expertise in chronic pain and neuropathic pain.

• Patients between 18 and 80 years old

• suffering from moderate to severe (VAS score >5/10) chronic (duration> 12 months) neuropathic (DN4 score = 4/10) unilateral pain - located in the upper limb.

• from peripheral origin, including complex regional pain syndrome type I and II, post-traumatic or post surgical pain.

• refractory to first and second line treatments for neuropathic pain according recent French recommendations and guidelines[6], including serotonin- noradrenaline reuptake inhibitor (SNRI) antidepressants (duloxetine and venlafaxine), gabapentin, pregabalin, tricyclic antidepressants, topical lidocaine, high-concentration capsaicin patches, psychotherapy and combinations of them.

Patient have signed informed consent

• Patient benefiting from French social insurance system

Exclusion Criteria:

• Brachial plexus avulsion

• Post-zoster neuropathic pain

• Phantom limb pain

• Patient unable to fill a self-administered questionnaire

• Patients with a chronic disease requiring repeated MRI monitoring

• Patients with contra-indication to general anesthesia, surgery or percutaneous BP approach.

• Patients with other pacemakers (cardiac pacemaker or defibrillator) or patients with a high risk to use a defibrillator due to a known cardiac disorder.

• Patients with instable neuropsychological or psychiatric disorders

• Vulnerable patients: pregnant or breast feeding, minor, adult under guardianship or deprived freedom

Related Conditions & MeSH terms

• Neuralgia

Intervention

Device:
• electrical stimulation of the brachial plexus nerve roots
treated by chronic electrical stimulation of the brachial plexus nerve roots

Other:
• sham stimulation
treated by sham stimulation

Locations

Country	Name	City	State
France	CHU de Lyon	Lyon
France	CHU de Nice	Nice
France	CHU de Poitiers	Poitiers

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Nice

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	efficacity	evaluation by the patient with quizz EQ5D (worse: 0-better: 20)	after 3 months of treatment
Primary	efficacity	evaluation by the patient with quizz VAS (worse: 0- better: 100)	after 3 months of treatment